SABI Mind - Our Second Year In Review
Looking back at our second year of practice, we remain grateful for the opportunity to support our clients, the growing body of science and our communities. SABI Mind experienced a year of growth, launching new initiatives and expanding our therapy options. We remain diligently focused on providing innovative treatments to those facing challenges.
Our Clients
We are dedicated to supporting our clients with careful, considered and measured approaches to navigating mental health and chronic pain conditions:
Over 250 patients supported
2000+ hours of services provided
Over $30,000 in funding for our Equitable Access Program
14.5% improvement in quality of life
26.3% improvement in depression
49% improvement in anxiety
43% improvement in trauma symptoms
Advancing Psychedelic Research
Global Psychedelic Survey: Unveiling New Perspectives
Throughout the past year, SABI Mind embarked on an ambitious project—the Global Psychedelic Survey (GPS), engaging over 6,400 individuals from 85 countries. This vast study shed light on patterns of psychedelic use, revealing preferences for psilocybin, the quest for legal access, and the drive behind usage for personal growth, therapeutic reasons, and recreation. Interestingly, the survey also documented a trend towards reduced substance use post-psychedelic experiences and highlighted a significant therapeutic impact on psychological and psychical health issues. These findings emphasize the growing need for a legal framework that supports safe access to psychedelics, advocating for their potential in mental health and personal development.
Research Publication: “Changed Substance Use after Psychedelic Experiences among Individuals in Canada”
Boehnke, K.F., Kruger, D.J., & Lucas, P (2023)
Our own Dr. Philippe Lucas contributed to a landmark study detailing the effects of psychedelic experiences on substance use. This research, drawing from Canadian participants, illuminates the transformative power of psychedelics in reducing dependency on substances like alcohol and antidepressants while fostering a deeper connection to self and the world. This work enriches our understanding of psychedelics’ therapeutic potential, underscoring the importance of integrating these substances into future healthcare strategies. Learn more.
Supporting Clinical Trials: Psilocybin-Assisted Psychotherapy for AUD
In a significant stride for psychedelic therapy, SABI Mind proudly supports the first Alberta-based clinical trial examining Psilocybin Assisted Psychotherapy for Alcohol Use Disorder in collaboration with Clairvoyant Therapeutics. This pioneering study, approved by HREBA, explores psilocybin’s potential to alter the treatment landscape for AUD. Initial findings pointing towards a decrease in heavy drinking highlight the promise of psilocybin-assisted therapy in addressing complex substance use disorders. This initiative, led by Dr. Lauren Zanussi and Sara Brooks, marks a pivotal moment in our mission to innovate within mental health care.
For detailed information on this clinical trial and our ongoing research endeavours, please visit www.sabimind.com/audstudy.
Full Circle Series
Over the past year, SABI Mind’s Full Circle event series has made significant strides in advancing the conversation around psychedelics, consciousness, and mental health. Hosting a range of virtual discussions and presentations, Full Circle brought together industry thought leaders, clinicians, and researchers to explore the multifaceted world of psychedelics. Highlights included the Global Psychedelic Survey, presented by President Philippe Lucas. Other sessions covered topics such as the neuroscience and philosophy of psychedelics, with contributions from experts like Sidath Rankaduwa and practical advice for health practitioners battling burnout from embodiment coach Gabriel Shaw. Additionally, Dr. Jessica McLachlan provided an in-depth discussion on psychedelic integration, emphasizing its importance in achieving lasting benefits from psychedelic-assisted therapy. These events, part of Full Circle’s unconventional healing space, aimed to illuminate consciousness through psychedelics and foster a deeper understanding of their potential in mental health and well-being.
For more information about our upcoming events, follow us here: https://www.eventbrite.ca/o/sabi-mind-47740932483
Podcast Appearances
Exploring Patient-Centric Ketamine Therapy on the Minority Trip Report Podcast
Heesoo Cho, the Co-Founder and Managing Director of SABI Mind, took to the Minority TripReport Podcast to share insights into our patient-first approach to ketamine-assisted psychotherapy. His discussion emphasized SABI Mind’s commitment to expanding access to psychedelic treatments for chronic mental health issues and pain, reflecting our deep-rooted dedication to exceptional care in our Calgary and Victoria clinics. This podcast appearance is a testament to our ongoing efforts to lead with compassion and innovation in mental health treatment.
Minority Trip Report Podcast with Heesoo Cho: Listen to the Episode
Philippe Lucas Sheds Light on Psychedelic Therapy’s Evolution on Current & Critical
SABI Mind’s President, Philippe Lucas, brought his extensive experience to the Current & Critical podcast hosted by Tyler Chisholm. As a pioneer in medical cannabis and a staunch advocate for the healing potential of psychedelic medicines, Lucas provided valuable insights into the rapid advancements in psychedelic therapy research. He highlighted compelling data from our ketamine trials and discussed the creation of the Wellness Fund to improve treatment accessibility. Lucas’s conversation underlines the crucial role of collaborative efforts in spearheading the psychedelic therapy movement in Calgary.
Current & Critical E320 with Philippe Lucas: Listen to the Episode
In the News
Over the past year, SABI Mind has been at the forefront of psychedelic research and therapy, with notable achievements and contributions that have captured attention in various media outlets:
1. PsyPost featured Dr. Philippe Lucas’s co-authored publication on the impacts of psychedelic experiences on substance use based on findings from the Canadian Psychedelic Survey.
2. Psychedelic Spotlight discusses the launch of the Global Psychedelic Survey, an extension of the successful Canadian Psychedelic Survey. This initiative aims to gather comprehensive data on psychedelic use worldwide. It underscores SABI Mind’s commitment to advancing psychedelic research and shaping future policies.
3. In an interview with reMind.com, Dr. Lucas discussed the ambitious goals of the Global Psychedelic Survey, which aims to attract thousands of participants globally. His insights reflect the potential impact of this research on developing regulatory models for psychedelic use.
4. The Edmonton Journal highlighted a pioneering clinical trial at SABI Mind, exploring the use of psilocybin in treating alcohol use disorder. This study represents a groundbreaking approach to addressing substance dependence through psychedelic-assisted psychotherapy.
5. Global News Morning Calgary featured Dr. Lauren Zanussi discussing Alberta’s only clinical trial using psilocybin to treat alcohol use disorder, spotlighting SABI Mind’s innovative efforts in mental health treatment.
6. Lastly, SABI Mind’s unique approach to clinic design was featured in the Netherlands-based FRAME magazine, emphasizing the integration of the Japanese philosophy of wabi-sabi. This recognition showcases SABI Mind’s commitment to creating healing environments that combine therapeutic efficacy with aesthetic harmony, marking a significant milestone in redefining mental health care spaces.
As we reflect on a year filled with groundbreaking research and significant contributions to the field of psychedelic science, we remain dedicated to pushing the boundaries of what’s possible in mental health treatment. Our journey continues with a focus on expanding our research, fostering community engagement, and advocating for informed policy changes that support the safe and beneficial use of psychedelics.
We are committed to innovation, accessibility, and the holistic well-being of those we serve. We’re eager to embark on new ventures and promise a year of growth, learning, and healing.
